# iBionext

iBionext is a Venture Capital based in Paris, France.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Paris, France
- **Region:** Europe
- **Address:** Paris, France
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** ibionext.com
- **LinkedIn:** https://www.linkedin.com/company/ibionext

## Regulatory record

- **Reports private funds:** No

## About

iBionext is a venture studio founded in 2015 in Paris, France. It creates, develops, and finances health tech startups through an ecosystem that matures and finances technologies. iBionext provides operational support and leads financing to maximize startup value.

## Sectors

- Digital Health
- AI/ML
- Biotech

## Questions

### How does iBionext source its investment opportunities?

iBionext originates most deals through proprietary relationships with French public research institutions including INSERM, CNRS, and major universities. The firm's team identifies promising scientific work before company formation, then assembles founding teams and intellectual property frameworks around those discoveries. This embedded sourcing model gives iBionext access to lab-stage projects that never reach open fundraising processes.

### Does iBionext invest outside France?

The firm's primary origination remains French academic and hospital systems, but iBionext has backed companies with pan-European operations. LynxCare, for example, is headquartered in Belgium and serves hospital networks across the EU. The firm will syndicate internationally when a portfolio company's clinical development pathway requires US or broader European co-investors.

### How is iBionext different from a standard VC firm?

iBionext functions as a venture studio for health-tech: it identifies academic research, creates companies around that research, and operates them through earliest-stage development before handing operational control to recruited management teams. This model means iBionext carries higher company-formation costs and deeper scientific due-diligence burdens than a fund evaluating external decks, but it captures proprietary deal flow that never reaches open markets.

## Related profiles

- [iB Hubs](https://altss.com/profile/ib-hubs)
- [IBIS Capital](https://altss.com/profile/ibis-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ibionext

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology